



September 2, 2025

**Announcement of launch of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination
Drug " CANALIA® Combination OD Tablets "**

~Adoption of a printing design with enhanced identifiability and visibility~

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, CEO: Akihisa Harada, "MTPC") launched CANALIA® Combination OD Tablets, which is the combination drug of selective DPP-4 inhibitor and SGLT2 inhibitor, today after it was listed in the National Health Insurance (NHI) price list on June 13.

CANALIA® Combination OD Tablets, which was approved on February 17, 2025, disintegrates easily in a small amount of water, dissolves quickly in saliva, and is easy to swallow. It can be taken with or without water, making it convenient to use regardless of location. It is expected to improve convenience and to continue taking the drug for people with type 2 diabetes who need continuous treatment.

In addition, a joint study was conducted with Sanyo-Onoda City University on the printed design of CANALIA® Combination OD Tablets to enhance its identifiability from visually similar products. The study was conducted among community pharmacists working at insurance pharmacies registered with the Yamaguchi Prefecture Pharmacists Association. It was found that a design emphasizing a single character significantly enhances identifiability and visibility.^{1), 2)}



The adoption of this design enables CANALIA® Combination OD Tablets to reflect user-oriented universal design and support the safe use of medicines.

MTPC will continue working to deliver the new treatment options for people living with type 2 diabetes to enhance satisfaction with treatment and convenience.

¹⁾ DOI: <https://doi.org/10.11256/jjdi.26.72>

²⁾ DOI: <https://doi.org/10.11256/jjdi.26.186>

Contact:

Mitsubishi Tanabe Pharma Corporation
CEO Office PR Group
+81-6-6205-5119